Wells Fargo Maintains Overweight on Enovis, Lowers Price Target to $39
Wells Fargo analyst Larry Biegelsen maintains Enovis (NYSE:ENOV) with a Overweight and lowers the price target from $40 to $39.
Read original at benzingaStocks · News reference
Canaccord Genuity Maintains Buy on Enovis, Lowers Price Target to $45
Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $50 to $45.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 12:27 PM
- Checked
- Aug 17, 2026, 12:27 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BTIG Maintains Buy on Enovis, Raises Price Target to $40
BTIG analyst Ryan Zimmerman maintains Enovis (NYSE:ENOV) with a Buy and raises the price target from $39 to $40.
Read original at benzingaEnovis Q2 Adj. EPS $0.90 Beats $0.85 Estimate, Sales $582.782M Beat $582.542M Estimate
Enovis (NYSE:ENOV) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.85 by 5.88 percent. This is a 13.92 percent increase over earnings of $0.79 per share from the same
Read original at benzinga